ISIN | LU2050612402 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD |
Fund Provider |
JPMorgan Asset Management (Switzerland) LLC
Dreikönigstrasse 37 Postfach 8022 Zürich Tel. +41 (0)44 206 86 00 |
Fund Provider | JPMorgan Asset Management (Switzerland) LLC |
Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally. |
Peculiarities |
Current Price * | 99.73 USD | 04.10.2024 |
---|---|---|
Previous Price * | 99.42 USD | 03.10.2024 |
52 Week High * | 110.81 USD | 28.02.2024 |
52 Week Low * | 83.34 USD | 31.10.2023 |
NAV * | 99.73 USD | 04.10.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 563,029,510 | |
Unit/Share Assets *** | 150,705,579 | |
Trading Information SIX |
YTD Performance | -2.33% |
29.12.2023 - 04.10.2024
29.12.2023 04.10.2024 |
---|---|---|
YTD Performance (in CHF) | -1.04% |
29.12.2023 - 04.10.2024
29.12.2023 04.10.2024 |
1 month | -2.64% |
04.09.2024 - 04.10.2024
04.09.2024 04.10.2024 |
3 months | +3.36% |
05.07.2024 - 04.10.2024
05.07.2024 04.10.2024 |
6 months | -4.11% |
04.04.2024 - 04.10.2024
04.04.2024 04.10.2024 |
1 year | +10.64% |
04.10.2023 - 04.10.2024
04.10.2023 04.10.2024 |
2 years | -9.01% |
04.10.2022 - 04.10.2024
04.10.2022 04.10.2024 |
3 years | -38.16% |
04.10.2021 - 04.10.2024
04.10.2021 04.10.2024 |
5 years | -14.34% |
06.03.2020 - 04.10.2024
06.03.2020 04.10.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Novartis AG Registered Shares | 3.37% | |
---|---|---|
Alnylam Pharmaceuticals Inc | 3.26% | |
Gilead Sciences Inc | 3.12% | |
Vertex Pharmaceuticals Inc | 3.09% | |
Ionis Pharmaceuticals Inc | 3.04% | |
Biomarin Pharmaceutical Inc | 3.01% | |
Krystal Biotech Inc | 2.96% | |
Vericel Corp | 2.95% | |
Amgen Inc | 2.94% | |
Bio-Techne Corp | 2.87% | |
Last data update | 31.08.2024 |
TER *** | 0.94% |
---|---|
TER date *** | 31.12.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.72% |
Ongoing Charges *** | 0.93% |
SRRI ***
|
|
SRRI date *** | 30.09.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |